{"schema_version":"secwatch.filing_event.v1","accession":"0001640334-26-000461","form_type":"8-K","ticker":"ARTL","cik":"0001621221","company_name":"ARTELO BIOSCIENCES, INC.","filed_at":"2026-03-17T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.662238+00:00","generated_at":"2026-05-15T10:28:01.820326+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Artelo Biosciences completes 1-for-3 reverse split; FY2025 net loss $12.9M, going concern","bullets":["1-for-3 reverse stock split effective March 10, 2026; shares reduced from 2.1M to ~708k.","FY2025 net loss of $12.9M, up from $9.8M in FY2024; accumulated deficit reaches $63M.","Cash and cash equivalents of $0.6M at Dec 2025; auditor includes going concern qualification.","Loss on debt extinguishment totaled $1.158M ($825k + $333k related party) in FY2025.","Convertible notes issued at 12% interest; total convertible debt of $609k at Dec 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001640334-26-000461","json":"https://secwatch.observer/filing/0001640334-26-000461.json","markdown":"https://secwatch.observer/filing/0001640334-26-000461.md","text":"https://secwatch.observer/filing/0001640334-26-000461.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1621221/000164033426000461/0001640334-26-000461-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1621221/000164033426000461/artl_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T10:28:01.820326+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}